Literature DB >> 19716042

Exercise performance in patients with pulmonary hypertension linked to cardiac magnetic resonance measures.

Gerin R Stevens1, Anuradha Lala, Javier Sanz, Mario J Garcia, Valentin Fuster, Sean Pinney.   

Abstract

BACKGROUND: The 6-minute walk distance (6MWD) is a useful measure of functional class and has been shown to predict mortality in patients with pulmonary hypertension (PH). Determinants of functional class in PH are incompletely understood. We hypothesized that cardiovascular structure and function, as determined by cardiac magnetic resonance (CMR) imaging, and cardiac hemodynamics, as determined by right heart catheterization (RHC), would predict 6MWD in adult patients with PH.
METHODS: Forty-three patients (32 women) with PH underwent RHC, CMR and 6MWD testing within a 3-month period. The 6MWD was correlated with RHC and CMR variables using Spearman rho (r) coefficients. These relationships were further evaluated using linear regression analysis.
RESULTS: Median 6MWD was 233.2 (interquartile range 161.6 to 338.4) meters. The 6MWD was correlated with pulmonary artery (PA) elasticity (r = 0.42, p = 0.006), PA average blood flow velocity (r = 0.38, p = 0.014), right ventricular stroke volume index (RVSVI; r = 0.41, p = 0.008), left ventricular SVI (LVSVI; r = 0.36, p = 0.018) and RV stroke work index (RVSWI; r = 0.37, p = 0.017). These associations remained significant after adjustment for age, gender, body mass index and the presence of lung disease. Exercise performance did not correlate with commonly measured indices such as ventricular volume, ejection fraction or pulmonary pressure.
CONCLUSIONS: Stroke volume index, PA elasticity and PA average blood flow velocity are novel CMR parameters associated with functional class in PH. CMR can provide insights into determinants of exercise performance and may be a useful tool to non-invasively monitor cardiovascular status in patients with PH.

Entities:  

Mesh:

Year:  2009        PMID: 19716042     DOI: 10.1016/j.healun.2009.05.004

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  5 in total

1.  Pulmonary arterial stiffness assessed by cardiovascular magnetic resonance imaging is a predictor of mild pulmonary arterial hypertension.

Authors:  Jordan C Ray; Charles Burger; Patricia Mergo; Robert Safford; Joseph Blackshear; Christopher Austin; DeLisa Fairweather; Michael G Heckman; Tonya Zeiger; Marcia Dubin; Brian Shapiro
Journal:  Int J Cardiovasc Imaging       Date:  2018-06-22       Impact factor: 2.357

2.  Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension.

Authors:  Mark R Toshner; Deepa Gopalan; Jay Suntharalingam; Carmen Treacy; Elaine Soon; Karen K Sheares; Nicholas W Morrell; Nicholas Screaton; Joanna Pepke-Zaba
Journal:  J Heart Lung Transplant       Date:  2010-03-15       Impact factor: 10.247

3.  Cardiac magnetic resonance-derived right ventricular outflow tract systolic flow acceleration: a novel index of right ventricular function and prognosis in patients with pulmonary arterial hypertension.

Authors:  Ki-Woon Kang; Hyuk-Jae Chang; Yeon Pyo Yoo; Hyeon Soo Yoon; Young-Jin Kim; Byoung-Wook Choi; Chi-Young Shim; Jongwon Ha; Namsik Chung
Journal:  Int J Cardiovasc Imaging       Date:  2013-07-17       Impact factor: 2.357

Review 4.  The role of pulmonary arterial stiffness in COPD.

Authors:  Jonathan R Weir-McCall; Allan D Struthers; Brian J Lipworth; J Graeme Houston
Journal:  Respir Med       Date:  2015-06-12       Impact factor: 3.415

5.  The predictive capabilities of a novel cardiovascular magnetic resonance derived marker of cardiopulmonary reserve on established prognostic surrogate markers in patients with pulmonary vascular disease: results of a longitudinal pilot study.

Authors:  Timothy J Baillie; Samuel Sidharta; Peter M Steele; Stephen G Worthley; Scott Willoughby; Karen Teo; Prashanthan Sanders; Stephen J Nicholls; Matthew I Worthley
Journal:  J Cardiovasc Magn Reson       Date:  2017-01-09       Impact factor: 5.364

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.